2Salvagno GL, I.ippi G, Montagnana M. Influence of temperature and time before centrifugation of specimens for routine coagula lion *esling[J]. Inl J Lab Hematol,2009,31(4) :462 - 467.
3Mackrnan N,Tilley BE,Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis[J]. Ateriosclero sis and Thrombosis Vascular Biology, 2007,27(8) :1687 - 1693.
4Burgazli KM, Atmaca N, Mericliler M,et al. Deep vein thrombo sis and novel oral anticoagulants: A clinical review[J], gur Rev Med Pharmacol Sci,2013,17(23) :3123 - 3131.
5Bowry R, Fraser S, Archeval-Lao JM, et al. Thrombelas- tography detects the anticoagulant effect of rivaroxaban in patients with stroke[J]. Stroke, 2014,45 (3) : 880-883.
6FelLer T, Kellermayer MS, Kiss B. Nano-thrombelastog- raphy of fibrin during blood plasma clotting[J]. J Struct Biol, 2014,186(3) :462-471.
7Power A,Epstein D,Cohen D,et al. Renal impairment re- duces the efficacy of thrombolytie therapy in acute ische- mie stroke[J]. Cerebrovasc Dis, 2013,35 ( 1), 45-52.
8Lip GY,Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for strokeprevention in atrial fibrillation[J]. J Am Coll Cardiol, 2012,60 (8) : 738-746.
9Potpara TS, Polovina MM, Licina MM, et al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban[J]. Adv Ther, 2012,29 (6) : 491-507.
